Dr. Staskin discusses counseling patients on vibegron for OAB

"Until a better option comes along, its low cost (mesh alone) and ease of use allows a standardized approach in an appropriately selected patient," writes Gopal H. Badlani, MD.

“This technique is feasible, it is very well tolerated, and there’s not much of a complication rate, so it appears to be very safe,” says Amy D. Dobberfuhl, MD, MS.

"We noted in our overall population, which was about 214 women, there was a 40% discontinuation rate for Botox treatments in the office," says Katherine L. Woodburn, MD.

“We need to improve the fact that 75% of these patients are untreated [or] unmanaged and frustrated,” says Alexandra Rogers, MD.

The pharmacokinetic drug GEMTESA, developed by Urovant Sciences, was given to adult patients as a single 75-mg dose in a phase 1 study.

eCoin is a new technology for the management of bladder overactivity that is implanted near the posterior tibial nerve subcutaneously.